Published in Pharmacogenet Genomics on November 01, 2012
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome. Clin Gastroenterol Hepatol (2013) 1.46
Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohort. PLoS One (2014) 1.39
Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity. Sci Rep (2017) 1.38
Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology (2013) 1.24
A collaborative approach to developing an electronic health record phenotyping algorithm for drug-induced liver injury. J Am Med Inform Assoc (2013) 1.14
Acetaminophen-induced Liver Injury: from Animal Models to Humans. J Clin Transl Hepatol (2014) 1.01
Pharmacogenomics of adverse drug reactions. Genome Med (2013) 1.00
Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol (2015) 0.92
Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury. Genome Med (2013) 0.87
Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury. Am J Gastroenterol (2016) 0.85
N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. Eur J Clin Pharmacol (2014) 0.81
Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics (2012) 0.81
Amoxicillin-Clavulanate-Induced Liver Injury. Dig Dis Sci (2016) 0.80
Signal transducer and activator of transcription 4 in liver diseases. Int J Biol Sci (2015) 0.80
Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity. BMC Genomics (2016) 0.79
Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study. Gastroenterology (2016) 0.77
Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury? Pharm Res (2016) 0.76
Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int (2015) 0.76
Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation. OMICS (2017) 0.75
Analysis of IL-6, STAT3 and HSPA1L gene polymorphisms in anti-tuberculosis drug-induced hepatitis in a nested case-control study. PLoS One (2015) 0.75
Emerging hepatotoxicity biomarkers and their potential to improve understanding and management of drug-induced liver injury. Genome Med (2013) 0.75
Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut (2017) 0.75
PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet (2007) 209.92
Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet (2006) 115.71
Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A (2009) 54.68
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol (1993) 7.63
WGAViewer: software for genomic annotation of whole genome association studies. Genome Res (2008) 7.15
The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research. Am J Hum Genet (2008) 4.79
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11
Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology (2005) 3.52
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
PGA: power calculator for case-control genetic association analyses. BMC Genet (2008) 2.71
A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet (2010) 2.68
A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet (2004) 2.44
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J (2007) 2.17
Power and sample size calculations in the presence of phenotype errors for case/control genetic association studies. BMC Genet (2005) 2.14
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol (2011) 1.60
STAT4: genetics, mechanisms, and implications for autoimmunity. Curr Allergy Asthma Rep (2008) 1.53
Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology (2008) 1.27
Liver tests are irrelevant when prescribing statins. Lancet (2010) 1.18
Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol (2011) 1.14
Drug-induced liver injury: past, present and future. Pharmacogenomics (2010) 1.11
Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma. Arch Immunol Ther Exp (Warsz) (2008) 1.11
Drug-induced liver injury: insights from genetic studies. Pharmacogenomics (2009) 1.10
EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics (2006) 0.97
Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol Pharmacol (2002) 0.92
Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin Gastroenterol Hepatol (2009) 0.87
Modulation of inflammatory changes in early stages of colon cancer through activation of PPARgamma by diclofenac. Eur J Cancer Prev (2010) 0.81
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
Finding the missing heritability of complex diseases. Nature (2009) 67.95
The complete genome of an individual by massively parallel DNA sequencing. Nature (2008) 52.81
Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet (2008) 30.94
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Efficiency and power in genetic association studies. Nat Genet (2005) 25.56
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Evolutionary and biomedical insights from the rhesus macaque genome. Science (2007) 16.21
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Rare variants create synthetic genome-wide associations. PLoS Biol (2010) 14.43
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Genes mirror geography within Europe. Nature (2008) 14.23
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab (2009) 11.46
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Common variants conferring risk of schizophrenia. Nature (2009) 10.37
Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet (2010) 9.53
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet (2007) 8.74
The genome sequence of taurine cattle: a window to ruminant biology and evolution. Science (2009) 8.23
Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature (2009) 8.12
Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A (2005) 8.10
Discerning the ancestry of European Americans in genetic association studies. PLoS Genet (2007) 7.81
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
De novo mutations in epileptic encephalopathies. Nature (2013) 7.42
A randomized trial of genotype-guided dosing of warfarin. N Engl J Med (2013) 7.18
WGAViewer: software for genomic annotation of whole genome association studies. Genome Res (2008) 7.15
A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet (2009) 6.93
The genome of the sea urchin Strongylocentrotus purpuratus. Science (2006) 6.41
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol (2007) 5.77
Genome-wide transcript profiles in aging and calorically restricted Drosophila melanogaster. Curr Biol (2002) 5.58
Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet (2013) 5.58
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Genome-wide patterns of population structure and admixture in West Africans and African Americans. Proc Natl Acad Sci U S A (2009) 5.39
De novo mutations in histone-modifying genes in congenital heart disease. Nature (2013) 5.15
AASLD position paper: the management of acute liver failure. Hepatology (2005) 5.09
Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol (2008) 5.08
Correlation between genetic and geographic structure in Europe. Curr Biol (2008) 5.02
Web-based, participant-driven studies yield novel genetic associations for common traits. PLoS Genet (2010) 5.02
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology (2014) 4.98
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood (2005) 4.91
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A (2006) 4.84
Whole population, genome-wide mapping of hidden relatedness. Genome Res (2008) 4.72
Caenorhabditis elegans mutant allele identification by whole-genome sequencing. Nat Methods (2008) 4.71
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature (2010) 4.64
Selection and evaluation of tagging SNPs in the neuronal-sodium-channel gene SCN1A: implications for linkage-disequilibrium gene mapping. Am J Hum Genet (2003) 4.58
Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene. PLoS Genet (2010) 4.29
Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am J Psychiatry (2011) 4.29
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11
An accurate mass tag strategy for quantitative and high-throughput proteome measurements. Proteomics (2002) 4.10
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 4.00
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med (2011) 3.93
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88